Ipsen : Feedback from conference call: deterioration in newsflow runs out, Buy vs Neutral
>Resilience and hope - Highlights:1- Defensive business: the group’s business was described by CEO/CFO (by franchise), as capable of strong resilience (Q1 sales: +8.7% cc, of which +12.5% in Specialty).The lead taken by Somatuline® at end March (+19.5%) compared to expectations tends to demonstrate that the drug is gaining market share (+20% est. in the US and >+10% est. in Europe) and is holding up well against the generic drug octreotide. The generic vers...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.